Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 1-(4-((4-(dimethylamino)piperidin-1-yl)carbonyl)phenyl)-3-(4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl)urea
2. Pf-05212384
3. Pki 587
4. Pki-587
5. Pki587
1. 1197160-78-3
2. Pki-587
3. Pf-05212384
4. Pki 587
5. 1-(4-(4-(dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea
6. Pki587
7. Pf-05212384 (pki-587)
8. Pf 05212384
9. Chembl592445
10. 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
11. 96265tnh2r
12. N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-n'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea
13. Gedatolisib (pf-05212384, Pki-587)
14. Pki-587; Pf-05212384
15. Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-n'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-
16. 1-(4-((4-(dimethylamino)piperidin-1-yl)carbonyl)phenyl)-3-(4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl)urea
17. Gedatolisib [usan:inn]
18. Unii-96265tnh2r
19. 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
20. Urea, N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-n'-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]-
21. Pk 587
22. Pk 1587
23. Gedatolisib(pki-587)
24. Gedatolisib [inn]
25. Gedatolisib (usan/inn)
26. Gedatolisib [usan]
27. Gedatolisib (pki-587)
28. Schembl32393
29. Gedatolisib [who-dd]
30. Gtpl7940
31. Dtxsid40152557
32. Ex-a028
33. Hms3748m11
34. Bcp01986
35. Bdbm50308135
36. Mfcd16875679
37. Nsc758256
38. Nsc801014
39. S2628
40. Zinc49757175
41. Akos005766013
42. Ccg-264662
43. Cs-0449
44. Db11896
45. Fe-0013
46. Nsc-758256
47. Nsc-801014
48. Sb16571
49. Ncgc00370777-01
50. Ncgc00370777-04
51. Ac-31519
52. Hy-10681
53. Ft-0700110
54. Pki-587,pf-05212384
55. A25474
56. D10635
57. J-004182
58. J-523339
59. Q27077788
60. Pki-587
61. 1197160-78-3
62. Pki587
63. Pki 587
64. N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-n'-(4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl)urea
65. N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-n'-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]urea
66. N-{4-[4,6-bis(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-n'-{4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl}urea
67. Vl1
| Molecular Weight | 615.7 g/mol |
|---|---|
| Molecular Formula | C32H41N9O4 |
| XLogP3 | 2.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 7 |
| Exact Mass | 615.32815082 g/mol |
| Monoisotopic Mass | 615.32815082 g/mol |
| Topological Polar Surface Area | 128 Ų |
| Heavy Atom Count | 45 |
| Formal Charge | 0 |
| Complexity | 913 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
ABOUT THIS PAGE
22
PharmaCompass offers a list of Gedatolisib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Gedatolisib manufacturer or Gedatolisib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Gedatolisib manufacturer or Gedatolisib supplier.
PharmaCompass also assists you with knowing the Gedatolisib API Price utilized in the formulation of products. Gedatolisib API Price is not always fixed or binding as the Gedatolisib Price is obtained through a variety of data sources. The Gedatolisib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Gedatolisib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gedatolisib, including repackagers and relabelers. The FDA regulates Gedatolisib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gedatolisib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Gedatolisib supplier is an individual or a company that provides Gedatolisib active pharmaceutical ingredient (API) or Gedatolisib finished formulations upon request. The Gedatolisib suppliers may include Gedatolisib API manufacturers, exporters, distributors and traders.
click here to find a list of Gedatolisib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Gedatolisib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Gedatolisib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Gedatolisib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Gedatolisib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Gedatolisib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Gedatolisib suppliers with NDC on PharmaCompass.
Gedatolisib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Gedatolisib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Gedatolisib GMP manufacturer or Gedatolisib GMP API supplier for your needs.
A Gedatolisib CoA (Certificate of Analysis) is a formal document that attests to Gedatolisib's compliance with Gedatolisib specifications and serves as a tool for batch-level quality control.
Gedatolisib CoA mostly includes findings from lab analyses of a specific batch. For each Gedatolisib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Gedatolisib may be tested according to a variety of international standards, such as European Pharmacopoeia (Gedatolisib EP), Gedatolisib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gedatolisib USP).